CanSino Biologics Stock (OTC:CASBF), Trade Ideas

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

Earnings

News

Health Care

Markets

General

BNTX

CASBF

MRNA

NVAX

SHTDY

Besides saving lives and the global economy, we are expecting three things from the upcoming COVID-19 vaccine: safety, immunogenicity and efficacy. But we never had a 100 percent efficacy when it comes to respiratory viruses, so anything between 50 and 100% will be the best we&#39;ve got as the WHO believes everything above 50 percent efficacy is acceptable.

Current Updates On COVID-19 Vaccines

Biotech

Events

Media

CanSino Biologics Inc (OTC: CASBF) partnership with Canada’s National Research Council on a COVID-19 vaccine came to an end Wednesday, Reuters 

CanSino, Canada End COVID-19 Vaccine Collaboration, Citing Chinese Bureaucratic Hurdles

Eurozone

Futures

Global

Pre-Market Outlook

PRNB

TDOC

Pre-open movers

U.S. stock futures traded higher in early pre-market trade, after recording gains in the previous week. The Empire State manufacturing index for August is scheduled for release at 8:30 a.m. ET, while the NAHB’s housing market index for August will be released at 10:00 a.m. ET.

A Peek Into The Markets: US Stock Futures Rise Following Prior Week&#39;s Gains

CANSINO BIOLGICS REG H by CANSINO BIOLOGICS INC

CanSino Biologics Inc

Fiscal Year 2024 Financial Outlook
Based on year-to-date performance and its outlook, Tractor Supply reiterates the following financial guidance for fiscal year 2024, initially provided on February 1, 2024:
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
Net Sales
</td>
<td colspan="1" rowspan="1">
$14.7 billion to $15.1 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Comparable Store Sales
</td>
<td colspan="1" rowspan="1">
(1.0%) to +1.5%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Operating Margin Rate
</td>
<td colspan="1" rowspan="1">
9.7% to 10.1%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Net Income
</td>
<td colspan="1" rowspan="1">
$1.06 billion to $1.13 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Earnings per Diluted Share
</td>
<td colspan="1" rowspan="1">
$9.85 to $10.50
</td>
</tr>
</tbody>
</table>
&nbsp;

Guidance

TSCO

Tractor Supply Reiterates FY2024 Outlook: GAAP EPS $9.85-10.50 vs $10.22 Est; Sees Sales $14.700B-15.100B vs $14.98B Est

On April 25, 2024, Celly Nu announced a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City.&nbsp;
FSD Pharma has also licensed unbuzzd, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. (&quot;Celly Nu&quot;) and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement.&nbsp;

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

FSD Pharma Provides Update From Celly Nu's Partnership With Six+One For Beverage Product unbuzzd

Comparable store sales increased 1.1%, as compared to an increase of 2.1% in the prior year&#39;s first quarter, driven by a comparable average transaction count increase of 1.3% and a comparable average ticket decline of 0.2%. Comparable store sales growth reflects strength in seasonal merchandise, partially offset by declines for year-round discretionary categories. Consumable, usable and edible products performed in line with the Company&#39;s overall comparable store sales increase.

Tractor Supply Q1 Comparable Store Sales +1.1%

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold.

Reiteration

Analyst Ratings

SAGE

Needham Reiterates Hold on Sage Therapeutics

Telsey Advisory Group analyst Dana Telsey maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Market Perform and maintains $155 price target.

Price Target

Telsey Advisory Group Maintains Market Perform on Estee Lauder Cos, Maintains $155 Price Target

Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.71 by 7.02 percent. This is a 10.91 percent increase over earnings of $1.65 per share from the same period last year. The company reported quarterly sales of $3.39 billion which was inline with analyst consensus estimate of $3.39 billion. This is a 2.88 percent increase over sales of $3.299 billion the same period last year.

Earnings Beats

Earnings Misses

Tractor Supply Q1 2024 GAAP EPS $1.83 Beats $1.71 Estimate, Sales $3.39B Inline With $3.39B Estimate

Palantir Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading lower in the&nbsp;<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session on Thursday.&nbsp;</a>
The AI giant inked a multi-year strategic partnership with clinical research organization Parexel to enhance and accelerate the delivery of safe and effective clinical trials for<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38426020/parexel-and-palantir-expand-collaboration-to-accelerate-clinical-data-delivery-and-power-clinical-" rel="noreferrer noopener">&nbsp;the world&#8217;s biopharmaceutical customers.</a>
Under the collaboration, Parexel will leverage Palantir&#8217;s Foundry and Artificial Intelligence Platform (AIP) to boost its clinical data platform.
The platform&nbsp;is focused&nbsp;on driving clinical trial efficiency while maintaining the highest&nbsp;level of&nbsp;safety and regulatory rigor.
&#8220;Leveraging our internal Parexel expertise and our strategic partnership with Palantir, we have novel solutions already in use or&nbsp;in&nbsp;various stages of development that demonstrate our commitment to&nbsp;be&nbsp;a fully digital CRO,&#8221; said Jonathan Shough, Chief Information Officer for Parexel.&nbsp;
Parexel is the first CRO working with Palantir in this capacity, building on the companies&#8217; existing collaboration over the past year, according to a press release.
Parexel Precision Pathway is an end-to-end operational approach that prioritizes the timely delivery of clean data while driving efficiency, quality&nbsp;and&nbsp;predictability.&nbsp;
&#8220;The company will significantly accelerate its business by&nbsp;untapping&nbsp;the value of data via an ontology constructed within Palantir Foundry and connecting it to the immense power of generative AI in AIP,&#8221;&nbsp;said Dr. Lalarukh Haris Shaikh,&nbsp;Executive,&nbsp;Life&nbsp;Sciences at Palantir.
Supported by Palantir&#8217;s software, Parexel&#8217;s clinical data platform provides an integrated digital environment to hyper-automate manual processes, promote data discoverability, distill insights from historical trials, and streamline coordination among&nbsp;scientific&nbsp;and operational teams and their partners.
Palantir&nbsp;is set&nbsp;to report its first-quarter financial results on May 6 after the market close. According to estimates from&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, analysts expect the company to report earnings of 8 cents per share and quarterly revenue of $625.33 million.&nbsp;
Price Action: PLTR shares are trading lower by 1.07% to $21.36 premarket at last check Thursday.
Photo via Shutterstock

Equities

Movers

PLTR

What's Going On With Palantir Technologies Today?

Asbury Automotive Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABG#NYSE">ABG</a>) reported quarterly earnings of $7.21 per share which missed the analyst consensus estimate of $7.63 by 5.5 percent. This is a 13.86 percent decrease over earnings of $8.37 per share from the same period last year. The company reported quarterly sales of $4.201 billion which missed the analyst consensus estimate of $4.264 billion by 1.48 percent. This is a 17.28 percent increase over sales of $3.582 billion the same period last year.

Asbury Automotive Gr Q1 2024 GAAP EPS $7.21 Misses $7.63 Estimate, Sales $4.201B Miss $4.264B Estimate

Rosenblatt analyst Andrew Bond reiterates CME Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Sell and raises the price target from $185 to $187.

Rosenblatt Reiterates Sell on CME Gr, Raises Price Target to $187

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul>
<li>Dividend Yield: 6.40%</li>
<li>Guggenheim analyst Vamil Divan initiated coverage on the stock with a Buy rating and a price target of $36 on Feb. 23, 2024. This analyst has an accuracy rate of 76%.</li>
<li>TD Cowen analyst Steve Scala downgraded the stock from Outperform to Market Perform with a price target of $32 on Jan. 4, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On April 24, Pfizer's board of directors declared a 42 cents second-quarter 2024 dividend on the company&#8217;s common stock.</li>
</ul>
<h3 class="wp-block-heading">Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</h3>
<ul>
<li>Dividend Yield: 4.59%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and cut the price target from $84 to $78 on March 4, 2024. This analyst has an accuracy rate of 76%.</li>
<li>RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and slashed the price target from $76 to $75 on Feb. 14, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: Gilead Sciences is expected to release first quarter 2024 financial results on Thursday, April 25.</li>
</ul>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 3.97%</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and cut the price target from $38 to $35 on Nov. 30, 2023. This analyst has an accuracy rate of 77%.</li>
<li>Stifel analyst Jonathan Block reiterated a Hold rating with a price target of $32 on Nov. 28, 2023. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On March 11, Patterson Companies approved a $500 million stock buyback and declared a quarterly dividend of 26 cents per share.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/24/04/38402061/jim-cramer-says-this-energy-stock-is-terrific-calls-caseys-general-stores-a-winner">Jim Cramer Says This Energy Stock Is &#8216;Terrific,&#8217; Calls Casey&#8217;s General Stores A &#8216;Winner&#8217;</a>

Dividends

Trading Ideas

GILD

PDCO

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields

WIIM

EMCOR Group shares are trading higher after the company reported better-than-expected Q1 financial results and increase FY24 guidance above estimates.

HC Wainwright &amp; Co. analyst Andrew Fein maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $325 to $300.

BIIB

HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $300

Rosenblatt analyst Barton Crockett maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $520 to $562.

Rosenblatt Maintains Buy on Meta Platforms, Raises Price Target to $562

Market-Moving Exclusives

Exclusives

VRAX

EXCLUSIVE: Virax Biolabs Tells Benzinga 'The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmuneTM  as a full In-Vitro-Diagnostic product'

Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.46 by 8.7 percent. This is a 56.14 percent decrease over earnings of $1.14 per share from the same period last year. The company reported quarterly sales of $1.420 billion which missed the analyst consensus estimate of $1.484 billion by 4.26 percent. This is a 20.71 percent decrease over sales of $1.791 billion the same period last year.

Darling Ingredients Q1 2024 GAAP EPS $0.50 Beats $0.46 Estimate, Sales $1.420B Miss $1.484B Estimate

Brunswick shares are trading lower following Q1 financial results and roughly in-line guidance.

EXCLUSIVE: Virax Biolabs Tells Benzinga Co. Launches Portfolio Of Immune Profiling Solutions Evaluating Adaptive Immunity In Post-Viral Syndromes

ConnectOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNOB#NASDAQ">CNOB</a>) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate of $0.42 by 2.38 percent. This is a 30.51 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $60.300 million which missed the analyst consensus estimate of $61.598 million by 2.11 percent. This is a 10.11 percent decrease over sales of $67.084 million the same period last year.

CNOB

ConnectOne Bancorp Q1 2024 GAAP EPS $0.41 Misses $0.42 Estimate, Sales $60.300M Miss $61.598M Estimate

BlackRock&#8216;s iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) has seen its <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38401088/bitcoin-spot-etfs-net-31-6m-inflows-as-hong-kong-readies-for-etf-launches">record-breaking streak of inflows</a> come to an end on Wednesday. 
What Happened: According to <a href="https://sosovalue.xyz/assets/etf">data </a>from SoSoValue, IBIT recorded no net inflows for the day, snapping a 71-day stretch of continuous investment. 
On Wednesday, spot Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ETF flows saw net outflows totaling $121 million, signaling a turbulent day for cryptocurrency investments.
Notably, Grayscale's Bitcoin Trust ETF (GBTC) registered the most substantial single-day outflow, withdrawing $130 million. 
Contrasting this, Fidelity Wise&#8217;s Origin Bitcoin Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>) emerged as the frontrunner for inflows, attracting $5.61 million in a single day, followed closely by the collaborative ETF from Ark Invest and 21Shares (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>), which saw an influx of $4.17 million.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38413962/jack-dorsey-wants-to-make-bitcoin-mining-as-easy-as-plugging-in-a-lamp-heres-how">Jack Dorsey Wants To Make Bitcoin Mining As Easy As Plugging In A Lamp: Here&#8217;s How</a>
Hong Kong Steps Into The Crypto ETF Arena
The news of BlackRock&#8217;s pause coincides with a significant development in the Asian market. 
HashKey Exchange announced the completion of the first-ever cryptocurrency subscription for Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) spot ETFs offered by Hong Kong-based Bosera International and HashKey Capital. 
This subscription model allows for redemption without immediate sale of the underlying assets, potentially offering cost and liquidity benefits to investors.
Hong Kong&#8217;s foray into cryptocurrency ETFs marks a potential turning point for the Asian market. 
These ETFs are expected to begin trading on the Hong Kong Stock Exchange on April 30, providing investors in the region with a new avenue for cryptocurrency exposure.
What&#8217;s Next: The Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event, scheduled for Nov. 19, will convene industry leaders, analysts, and investors to discuss these critical developments. 
This conference presents a unique opportunity to gain insights into the future of Bitcoin ETFs, cryptocurrency subscriptions, and the broader digital asset ecosystem. 
Don&#8217;t miss out on this chance to stay ahead of the curve in this <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38412858/trumps-crypto-portfolio-rebounds-with-1m-weekly-profit-which-crazy-new-currencies-does-he-">rapidly changing market.</a>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38408395/why-is-mog-crypto-coin-going-up-trader-sees-billions-as-price-target">Why Is MOG Crypto Coin Going Up? Trader Sees &#8216;Billions&#8217; As Price Target</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

BlackRock's Spot Bitcoin ETF Sees Zero Inflows, As Net Outflows Tally $130M On Wednesday

Jason Tsai, currently VP of IR and Finance at Silicon Motion, has been appointed Interim Chief Financial Officer of the Company effective as of April 25, 2024.&nbsp;

Management

SIMO

Silicon Motion Says Riyadh Lai Will Be Stepping Down As CFO, Effective April 25, 2024; Jason Tsai Named As Interim CFO

WHO meeting is set to decide whether to end COVID emergency

Fosun Pharmaceutical, CanSino Take Different Paths As Covid Lift Fade

WHO recommends updating COVID shots to add XBB.1 variants

AstraZeneca inks mRNA vaccine deal with China's CanSino

BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies raised $100 million in a private placement.